Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead covalent PI3Kα inhibitor, and additional ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.

Novartis won FDA approval for its PI3Kα inhibitor Piqray in 2019. Roche’s Itovebi joined the party late last year. Lilly’s attempt to follow its peers took a hit last year when it axed LOXO ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to acquire ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ...

Submit an IND application for CGT6737, a potent allosteric inhibitor of PI3Kα, with 25-fold selectivity over PI3Kα WT. Cogent will participate in a presentation and Q&A session at the 43rd ...